Introduction
Human herpesvirus-6 (HHV-6) is a member of the Roseolovirus genus of the b-herpesvirus subfamily with 490% seroprevalence. Like other herpesviruses, HHV-6 is thought to remain latent after primary infection, reactivating under conditions of immunosuppression.
HHV-6 has increasingly been recognized as an opportunistic and potentially life-threatening pathogen for recipients of allogeneic SCT. The virus is associated with rash, 1 delayed platelet engraftment, 2-4 encephalopathy [3] [4] [5] [6] [7] [8] [9] and allcause mortality 3 among such patients. An increasing number of clinical reports have suggested that HHV-6 represents an important emerging pathogen for central nervous system complications accompanying SCT. Previous case reports have shown that HHV-6 encephalopathy displays various unique characteristics, including: (1) short-term memory dysfunction; (2) symptoms appearing close to the time of engraftment and (3) signal hyperintensity in the limbic area on T2-weighted magnetic resonance imaging. [4] [5] [6] [7] 9, 10 Mortality rates for HHV-6 encephalopathy are high, and surviving patients often display lingering neurological compromise. [4] [5] [6] [7] [8] However, no consensus has been reached regarding the most appropriate preventative methods for HHV-6 encephalopathy.
HHV-6 levels in plasma correlate well with indicators of active replication. 8 Several investigations into the incidence and clinical significance of HHV-6 reactivation in allogeneic SCT using quantitative PCR assay for plasma have been reported. 3, 4, 9 These studies have shown approximately half of patients undergoing SCT developed active HHV-6 infection, with peak infection occurring 3-4 weeks after SCT, and only rarely causing encephalopathy. 3, 4, 9 We found that in patients with HHV-6 detected in plasma, HHV-6 DNA level was higher from patients who developed limbic encephalitis. 4 In the same study, we showed the possibility that virus copy number allowing prediction of HHV-6 encephalopathy is 41-2 Â 10 4 copies/ml plasma. 4 This prospective, pilot study investigated the efficiency of a plasma HHV-6 DNA-guided preemptive approach for preventing HHV-6-associated central nervous system dysfunction.
Patients and methods
This study involved consecutive patients who received hematopoietic SCT at Oita University Hospital or Oita Prefectural Hospital between December 2004 and December 2006. Patients who died from any cause within 21 days of SCT and patients who received a second transplant were excluded, resulting in a final total of 29 subjects. Patient characteristics are summarized in Table 1 . As prophylaxis against herpes simplex virus infection, acyclovir was administered orally at 1000 mg/body in divided doses up to 35 days, followed by long-term low-dose (400 mg/body) oral administration until the end of immunosuppressive therapy.
After written informed consent was obtained from each patient, EDTA-treated peripheral blood was collected weekly. Blood sample collection was started on a median of day 4 after transplantation (range, days 0-16), and lasted until a median of day 72 (range, days 23-151). Median number of blood samples per patient was 11 (range, days 3-21). A total of 308 samples obtained from 29 patients were examined.
Plasma HHV-6 DNA copy numbers were measured using real-time PCR method, as described previously. 4 The detection limit was approximately 50 copies/ml plasma. Viral copy numbers were provided to physician the day after sampling, and were defined as low level (o1000 copies/ml plasma), mid level (1000-9999.5 copies/ml plasma) or high level (X10 000 copies/ml plasma). Patients with mid-level viral loads were kept under close observation, and reexamination was performed 3-4 days later if requested by the physician.
Patients showing high-level viral loads received preemptive administration of i.v. ganciclovir at a dosage of 5-10 mg/kg/ day. For patients whose hematopoiesis was still insufficient, the physician could delay initiation of ganciclovir treatment. HHV-6 subtype was determined by nucleotide sequence method (ABI Prism 310, Applied Biosystems, Foster City, CA, USA) of samples containing high-level viral DNA.
Presence of encephalopathy was defined as identification of clinical symptoms including seizure, loss of consciousness, confusion, disorientation or memory loss without identified etiology (for example, cerebral hemorrhage or infarction).
Subsequent positive rate of plasma HHV-6 DNA with or without ganciclovir therapy was compared using the Kaplan-Meier method (data not shown) and differences between groups were compared using the log-rank test (Prism 4 for Macintosh, GraphPad Software).
Results
Nineteen of the 29 recipients (65.5%) displayed positive HHV-6 DNA in plasma. Onset of positive HHV-6 DNA results occurred at a median of day 19 (range, days 4-87) after SCT. According to Kaplan-Meier analysis, overall cumulative rate of positive results for HHV-6 DNA in plasma by day 70 was 62.0%, and cumulative rate of developing positive HHV-6 DNA with X10 000 copies/ml plasma by day 70 was 32.4% ( Figure 1 ). Median maximum plasma HHV-6 DNA load among positive cases was 4593.5 copies/ml plasma (range, 150.0-127 891.0 copies/ml plasma).
To evaluate the risk of exacerbating HHV-6 infection in each viral load group, subsequent kinetics of HHV-6 DNA were analyzed. Among the eight patients who developed low-level HHV-6 DNA, plasma DNA disappeared without reappearance in three patients and reappeared after disappearance in four patients and continued increasing Preemptive therapy against HHV-6 encephalitis M Ogata et al in one patient (Figure 2a) . Among the seven patients who developed mid-level HHV-6 DNA, plasma DNA disappeared without reappearance in two patients, reappeared after disappearance in one patient and continued increasing in four patients (Figure 2b ). Among the four patients for whom plasma HHV-6 continued increasing, one patient developed encephalopathy when HHV-6 DNA exceeded 10 000 copies/ml plasma. High-level HHV-6 DNA was identified in nine patients. Low-or mid-level HHV-6 DNA was detected before onset of high-level HHV-6 DNA in four patients, but these signs could not be confirmed before onset of high level in other five patients. Typing studies of HHV-6 DNA from this group revealed HHV-6 variant B in all nine patients. Ganciclovir was administered to six of the nine patients with high-level viral DNA, as a preemptive administration in four patients and for the treatment of complicated encephalopathy in two patients. The remaining three patients did not receive preemptive ganciclovir, as hematopoiesis was still insufficient. Subsequent kinetics of high-level viral DNA in groups with or without ganciclovir therapy are shown in Figure 3 . Ganciclovir therapy did not affect the disappearance of plasma HHV-6 DNA (P ¼ 0.38, log-rank test).
Case reports
Two patients developed encephalopathy. At the onset of encephalopathy, plasma HHV-6 viral loads reached to high level in each patient. The remaining 27 patients did not experience encephalopathy. Clinical courses of the two patients with encephalopathy are shown in Figure 4 and the details are described below.
Case 1: The patient was a 56-year-old man who received two-loci mismatched cord blood transplantation for the treatment of refractory adult T-cell leukemia (ATL). The conditioning regimen consisted of i.v. CY 60 mg kg À1 once daily for 2 days (total dose 120 mg kg À1 ) followed by TBI 4 Gy for 3 days, and prophylaxis against GVHD comprised cyclosporin A and MTX.
Due to complicated renal failure, administration of cyclosporin A was stopped on day 20. On day 28 after SCT, plasma HHV-6 DNA load became 9889.0 copies/ml plasma. On day 33, short-term memory loss and mental confusion developed. Magnetic resonance imaging on day 33 showed no obvious abnormalities. Lumbar puncture could not be performed due to severe thrombocytopenia. Treatment with ganciclovir (5 mg kg À1 twice daily i.v.) was empirically initiated on day 33. Seizures developed the next Duration from the day on which HHV-6 DNA reached 1000-9999 copies/ml (days) Duration from the day on which HHV-6 DNA became positive but <1000 copies/ml (days) Figure 2 Analysis for subsequent kinetics of human herpesvirus 6 (HHV-6) DNA loads in plasma after the day on which plasma viral DNA elevated to low-level HHV-6 DNA (a) or to mid-level HHV-6 DNA (b). Shaded area indicates values below threshold of detection (o50 copies/ml plasma). Arrows indicate day on which plasma HHV-6 loads shows 50-999.5 copies/ml plasma (a) or 1000-9999.5 copies/ml plasma (b). In two cases, low-level viral DNA increased to mid-level viral DNA, and kinetics for the two cases are repeated in (a) and (b) (data shown by asterisk symbol). day (day 34) and mechanical ventilation was initiated. HHV-6 DNA load on day 34 was 19 432.0 copies/ml plasma (subtype, variant B). HHV-6 DNA on day 30, that is 3 days before onset of neurological symptoms, was retrospectively measured using preserved plasma, and load was 20 951.0 copies/ml plasma. Results of examination for other pathogens were as follows: blood culture for bacterial and fungal organisms on day 33 was negative; PCR analysis of plasma on day 33 was negative for herpes simplex virus, but positive for CMV (1337.5 copies/ml plasma); and CMV antigenemia test on day 35 was negative. Neutrophil engraftment appeared on day 35 and ATL relapsed on day 53. Weaning from ventilation was not possible until his death on day 63. ) and TBI 4 Gy for 2 days, while prophylaxis against GVHD comprised tacrolimus and MTX.
Plasma HHV-6 DNA load were below the limit of detection (o50 copies/ml plasma) on day 11 after transplantation. On day 17, neurological status changed dramatically with loss of consciousness. Magnetic resonance imaging on day 17 revealed multiple white matter lesions and the patient became comatose on day 18. HHV-6 DNA load on day 19 was 105 414.0 copies/ml plasma (subtype, variant B). Blood cultures for bacterial and fungal organisms on day 16 and day 20 were negative, and CMV antigenemia test on day 19 was negative. Blood concentration of tacrolimus on day 19 was 15.7 ng/ml. Treatment with ganciclovir (5 mg kg À1 twice daily, i.v.) was initiated on day 19. Repeated magnetic resonance imaging on day 22 revealed strong bilateral signal abnormalities in the region of the hippocampus and multiple white matters (Figure 4) . To exclude the possibility of tacrolimus-induced encephalopathy, we stopped administration of tacrolimus from day 22 to day 25, but neurological symptoms did not improve. PCR analysis of cerebrospinal fluid (CSF) on day 25 revealed positive results for HHV-6 DNA (120 copies/ml plasma). Neurological symptoms temporarily improved after initiation of ganciclovir treatment, but the patient died of ATL 164 days after SCT.
Discussion
At least 48 SCT recipients with HHV-6-associated encephalopathy have been reported to date. 7 We have reported that in patients with HHV-6 detected in plasma, HHV-6 DNA load was higher in patients who had developed limbic encephalitis. 4 Although the pathogenic roles of HHV-6 in the development of encephalopathy require further exploration, HHV-6 has been recognized as an important emerging pathogen for central nervous system complications accompanying SCT.
CMV is another member of the b-herpesvirus subfamily and preemptive approaches against asymptomatic CMV reactivation successfully prevent the development of CMV pneumonia. 11, 12 Two studies suggest prophylaxis with ganciclovir can prevent HHV-6 reactivation in SCT recipients.
13,14 HHV-6 reactivation typically concentrates around the time of engraftment, and universal prophylaxis with ganciclovir may be problematic due to its toxicity against hematopoietic function. We hypothesized that preemptive approaches against HHV-6 reactivation guided by plasma HHV-6 DNA may be useful to prevent the development of HHV-6 encephalopathy.
Analysis of subsequent kinetics for plasma HHV-6 DNA suggests that low levels of HHV-6 DNA in plasma tend to disappear within 1 week. HHV-6 DNA load of 1000-9999.5 copies/ml plasma suggest subsequent progression of HHV-6 infection. Antiviral prophylaxis might be needed in this group. Among the nine patients with plasma HHV-6 DNA load exceeding 10 000 copies/ml plasma, two developed encephalopathy. Development of neurological symptoms corresponded to the peak load of HHV-6 DNA in each patient. This finding corresponds to the results of our previous study, with plasma HHV-6 DNA load 410 000-20 000 copies/ml plasma associated with the development of encephalopathy. 4 Conversely, HHV-6 DNA decreased from more than 10 000 copies/ml plasma to less than the detection limit in three patients who did not receive ganciclovir. These observations show the difficulty of matching decisions against HHV-6 viral loads.
In this study, HHV-6 infection was more frequent and maximum plasma loads of HHV-6 were relatively high, compared with those in patients in our previous study. 4 Such differences are probably associated with differences in patient background. HHV-6 infection is more frequently seen in cord blood SCT recipients, 15 and recipients from HLA-mismatch donors. 4, 7 In this study, about one-third of patients underwent cord blood SCT, and about half of patients received a transplant from an HLA-mismatched donor. In addition, 34.5% of patients had a diagnosis of ATL. Notably, both patients who developed encephalopathy received SCT for treatment of refractory ATL. Cellular immunodeficiency associated with ATL 16 may be associated with the development of HHV-6 encephalopathy.
Although asymptomatic patients with high levels of HHV-6 DNA in CSF samples have been described, 17 data from Wang et al. 18 and multiple case reports suggest that detection of HHV-6 DNA in CSF is significant 7 for the diagnosis of HHV-6 encephalopathy. In the present study, two patients developed encephalopathy that corresponded to high plasma HHV-6 viral loads. Impairment of short-term memory before the development of seizures corresponded with the typical clinical course of HHV-6 encephalopathy in case 1, and HHV-6 involvement in CSF was demonstrated 8 days after the development of encephalopathy in case 2. Neither patient, however, could undergo examination of CSF at the time for the development of encephalopathy, as platelet counts were low (13 Â 10 9 /l and 7 Â 10 9 /l, respectively) despite daily platelet transfusion. Onset of HHV-6 encephalopathy began a median of 24 days after SCT, 7 and HHV-6 is associated with delayed platelet engraftment. [2] [3] [4] If possible, CSF examination should be performed for patients with posttransplant limbic encephalitis or displaying distinctive clinical symptoms featuring short-term memory loss, amnesia and seizure. In patients showing these features but who could not undergo CSF examination due to bleeding tendency, we think that high levels of plasma HHV-6 DNA (probably 410 000 copies/ml plasma) are suggestive of HHV-6 encephalopathy, and may allow earlier initiation of treatment.
Notably, two patients developed encephalopathy despite monitoring plasma HHV-6 load weekly. In one case (Case 1), HHV-6 DNA in plasma on day 28 after SCT was 9889.0 copies/ml plasma, and initiation of ganciclovir was delayed as engraftment had not been achieved and viral loads were o10 000 copies/ml plasma. Encephalopathy developed on day 33. Later assay confirmed that plasma HHV-6 DNA load on day 30 (3 days before the onset of encephalopathy) had already reached 20 000 copies/ml plasma. In another case, plasma HHV-6 viral load elevated from o50 copies/ml plasma to 4100 000 copies/ml plasma within 1 week, and encephalopathy developed coincidently. These episodes of encephalopathy might have been preventable if the day on which plasma HHV-6 DNA reached high level could have been identified precisely and effective antiviral therapy initiated immediately. Plasma HHV-6 DNA loads, however, elevated suddenly over a short time. To identify the day on which plasma HHV-6 DNA reached high level, quantification of plasma HHV-6 viral loads will be necessary more than 3 times/week, and the results should be reported to the physician the day after plasma sampling at the latest. This seems impossible at institutes in which real-time PCR assay is not performed.
In conclusion, our preemptive approach cannot prevent all cases of HHV-6 encephalopathy in SCT recipients due to the dynamic kinetics of plasma HHV-6 viral load. To improve the ability of the preemptive approach, re-setting of appropriate viral loads to initiate anti-viral agents, more frequent assay, or monitoring by other markers such as whole blood 19 might be useful. Against high-risk SCT recipients for HHV-6 encephalopathy, however, clinical trials based on prophylactic strategies are warranted. Universal prophylaxis with ganciclovir may be problematic due to toxicity against hematopoietic function. We propose that prophylaxis with low-dose foscarnet might be more appropriate.
